With strong international backing, in 2010 Unitaid founded the Medicines Patent Pool, the first voluntary licensing and patent pooling mechanism in public health. Initially focused on improving the HIV response, Unitaid’s Executive Board approved the MPP’s entry into the fields of hepatitis C and tuberculosis in 2015. Unitaid is the MPP’s sole funder for these activities.
The MPP is currently operating under its second five-year grant from Unitaid (2016-2020).
Access the Memorandum of Understanding (2016-2020)
Unitaid is engaged in finding new ways to prevent, treat and diagnose HIV/AIDS, tuberculosis and malaria more quickly, more affordably and more effectively. It takes game-changing ideas and turns them into practical solutions that can help accelerate the end of the three diseases. The MPP is important in implementing Unitaid’s objectives by working with a range of organisations to license key medicines for generic manufacture.
Unitaid’s investments in the MPP have yielded 10.9 times the value of its funding, from price reductions of generic products. Savings are projected to reach 2.3 billion by 2028 for HIV medicines alone.
The Swiss Agency for Development and Cooperation (SDC) funded the MPP’s feasibility study exploring the expansion of its mandate to include other patented priority essential medicines beyond HIV, hepatitis C and tuberculosis.
The SDC is now funding the MPP to implement its mandate expansion into patented essential medicines on the World Health Organization’s (WHO) Essential Medicines List (EML) – and those with strong potential for future inclusion.
More on the SDC’s mission here.
Read press release.
The Wellcome Trust funds the MPP to concentrate on the key elements integral to implementing the MPP’s expanded mandate, including developing an implementation plan for the MPP’s new five-year strategy and exploring the MPP’s role in relation to antimicrobial resistance.
Read The Wellcome Trust’s statement on equitable access to healthcare interventions here.
Read press release